{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
NCT01882218: Phase 4 Interventional Withdrawn Hepatic Cancer
(2012)
Source URL:
First approved in 1995
Source:
ANDA074076
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Galactose, a monosaccharide sugar, is a key source of energy and is an important compound for early human development. Galactose is present in dairy products, the pectin of some fruits, vegetables, and some herbs. Children get most of their dietary galactose from milk. D-galactose is freely available in health food stores and is promoted for stimulating the immune system and improving gut motility in healthy individuals. Galactose as a part of food supplement participates in phase II of clinical trials for congenital disorders of glycosylation (CDG) patients. CDG is a group of more than 130 inborn errors of metabolism affecting N-linked, O-linked protein and lipid-linked glycosylation. In addition, monosaccharide is used in clinical trials phase I in patients with focal segmental glomerulosclerosis (FSGS), where the galactose lowers the level of a circulating factors that increase glomerular permeability to albumin in patients with resistant FSGS.
Status:
Possibly Marketed Outside US
Source:
Sedofarmolo by Centralvet
Source URL:
First approved in 1995
Source:
ANDA077614
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Possibly Marketed Outside US
First approved in 1995
Source:
NDA020551
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Benzenesulfonic acid (conjugate base benzenesulfonate) is the simplest aromatic sulfonic acid, that is soluble in water and ethanol, slightly soluble in benzene and insoluble in nonpolar solvents like diethyl ether. Benzenesulfonic acid was first obtained, together with diphenyl sulfone, by E. MITSCHERLICH in 1834 by heating benzene with fuming sulfuric acid. The industrially important reaction of benzenesulfonic acid with alkali hydroxide to form phenol (alkali fusion) was developed by A. WURTZ and A. KEKUL_e in 1867 and by P. O. DEGENER in 1878. Until the early 1960s benzenesulfonic acid was used chiefly in the manufacture of phenol. Benzenesulfonic acid has the characteristic reactions of a strong aromatic sulfonic acid. Acid hydrolysis at 175 C splits it into benzene and sulfuric acid. Additional sulfonation with fuming sulfuric acid gives 1,3-benzenedisulfonic acid, which reacts further to 1,3,5-benzenetrisulfonic acid, and also diphenyl sulfone disulfonic acid. Benzenesulfonic acid is used as an acid catalyst. The sodium salt is used to standardize dyes. A variety of pharmaceutical drugs are prepared as benzenesulfonate salts and are known as besilates (INN) or besylates (USAN).
Status:
Possibly Marketed Outside US
Source:
NCT04162834: Phase 4 Interventional Completed Kidney Cancer
(2019)
Source URL:
First approved in 1995
Source:
Papaverine Hydrochloride by American Regent, Inc.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. Papaverine is a vasodilating agent. Papaverine is used for the treating certain conditions that are accompanied by smooth muscle spasms (eg, blood vessel, urinary, gallbladder, or intestinal spasm). Papaverine is a nonxanthine phosphodiesterase inhibitor for the relief of cerebral and peripheral ischemia associated with arterial spasm and myocardial ischemia complicated by arrhythmias. The main actions of Papaverine are exerted on cardiac and smooth muscle. Like qathidine, Papaverine acts directly on the heart muscle to depress conduction and prolong the refractory period. Papaverine relaxes various smooth muscles. This relaxation may be prominent if spasm exists. The muscle cell is not paralyzed by Papaverine and still responds to drugs and other stimuli causing contraction. The antispasmodic effect is a direct one, and unrelated to muscle innervation. Papaverine is practically devoid of effects on the central nervous system. Papaverine relaxes the smooth musculature of the larger blood vessels, especially coronary, systemic peripheral, and pulmonary arteries. Papaverine is a potent, specific inhibitor of PDE10A. Papaverine for treatment of erectile dysfunction (ED) is excluded from coverage.
Status:
Possibly Marketed Outside US
Source:
ANDA078730
(1995)
Source URL:
First approved in 1995
Source:
ANDA078730
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2015)
Source URL:
First approved in 1995
Source:
M017
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
HYDROXYETHYLETHYLENEDIAMINETRIACETIC ACID (HEDTA) is used in cosmetics and care products. It’s a chelating agent, which in combination with selenium was effective in reducing the concentration of Al and level of DNA damage. In addition, experiments with rodents have shown that combination of HEDTA and propolis preserved histological features, mitigated oxidative stress and improved liver, kidney, and brain functions more profoundly.
Status:
Possibly Marketed Outside US
Source:
Ambrobeta by Betapharm
Source URL:
First approved in 1995
Source:
ANDA077614
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Amoproxan (Mederel, Mexderel), a coronary artery dilator and anti-arrhythmic, apparently withdrawn from production, produced pellagroid skin changes and several cases of axial optic neuropathy in France.
Status:
Possibly Marketed Outside US
Source:
Volu-Firm
Source URL:
First approved in 1995
Class (Stereo):
CHEMICAL (ACHIRAL)
Sodium myristate is the sodium salt of myristic acid. It is used in the food as the binder, emulsifier and anticaking agent. It is one of the commonly occurring soaps. It is used in cosmetic as a cleansing and emulsifying agent.
Status:
Possibly Marketed Outside US
Source:
ANDA208784
(1995)
Source URL:
First approved in 1995
Source:
ANDA208784
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
Canderel by Schlatter, J.M.
Source URL:
First approved in 1995
Source:
ANDA210465
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Aspartame (l-aspartyl-l-phenylalanine methyl ester) known to the public as NutraSweet has been the subject of controversy since it first became an ingredient in food products. The perceived sweetness of aspartame in humans is due to its binding of the heterodimer G-protein coupled receptor formed by the proteins TAS1R2 and TAS1R3. Aspartame was used in experiments on animals to study its role in delays of osteoarthritis. It was shown, that aspartame improved bone cortical density and muscle mass, and might contribute to a better quality of life for these diseased animals. In addition, was investigated the effect in patients with sickle cell anemia. It was revealed, that oral administration of aspartame lead inhibition of sickle cells. That effect was explained by binding aspartame with two human Bence Jones proteins: Mcg and Sea. Thus was suggested, that aspartame could interfere with sickle hemoglobin fibril formation. Then several studies showed that aspartame had no effect on the polymerization of sickle hemoglobin.